Subscribe And Get My Articles Emailed Directly To You - It's Free!!

Disclaimer

The following disclosures relate to my relationship with securities or issuers covered by this blog (or any other blog), or in tweets, or through my employer.

ANALYST DISCLOSURES


I am an employee of Zacks Investment Research (ZIR) and Managing Director and Senior Biotechnology Analyst at Zacks Small-Cap Research (SCR). This blog is separate from ZIR and SCR, and investors should assume that personal opinions expressed on this blog or in my Twitter (@JNapodano) are in no way associated with that of my employer, ZIR, unless otherwise specifically noted. A separate disclosure policy for Zacks SCR can be found on the SCR website, or via this link.

I, Jason Napodano, CFA, hereby certify that the view expressed on this or any other blog, or in my Twitter, accurately reflect my personal views about the subject securities. I also certify that I receive no compensation from this blog or my Twitter, directly or indirectly, related to the recommendations or views expressed on this or any other blog, or from my employer, ZIR, on securities or issuers covered on this blog or comments made on my Twitter. I believe the information used for the creation of articles for this or any other blog or tweets has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed on this or any other blog or via Twitter are subject to change without notice. Investors should refer to the SCR website for my most up-to-date investment recommendation on securities and issuers covered through my employer, ZIR or SCR, and not rely solely on this or any other blog, or my Twitter, for information about subject companies.

At times, I submit articles under Seeking Alpha's Premium or Pro programs, which pays on a per click or set rate per article. At times, I submit articles to PropThink, which pays me a set rate per article. I receive compensation from Google Adsense for advertising seen on this blog.

INVESTMENT BANKING, REFERRALS, AND FEES FOR SERVICE

I do not provide nor have I received compensation for investment banking services on the securities covered on this blog or via my Twitter. I do not expect to receive compensation for investment banking services from issues covered by this blog or via my Twitter. However, my employer, SCR or ZIR, may seek to provide referrals for a fee to investment banks. LBMZ Securities, a separate legal entity from ZIR and SCR, and this blog, is, among others, one of these investment banks. Referrals may include securities and issuers noted on this blog or via my Twitter. LBMZ Securities, Zacks & Co., or other independent investment banks may have paid referral fees to my employer, SCR, related to some of the securities and issuers noted on this blog or in my Twitter. From time to time, SCR pays investment banks, including LBMZ Securities, a referral fee for research coverage. As Managing Director for SCR, I am privy to information on referrals between LBMZ Securities and SCR or ZIR.

SCR may have received compensation for non-investment banking services, and expects to receive additional compensation for non-investment banking services from securities or issuers reported on in this or any other blog or on my Twitter. Non-investment banking services include investor relations services and software, investor targeting, financial database analysis, advertising services, brokerage services, advisory services, equity research, earnings estimates and consensus data, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by LBMZ Securities, ZIR, or SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees are paid to LBMZ Securities and/or ZIR. No fees are paid directly to me to provide any of the above services to issuers covered on this or any other blog or via my Twitter. No fees are paid directly to SCR to provide specific recommendations with respect to investment research coverage. Not all securities or issuers covered on this blog or via my Twitter have investment banking or non-investment banking relationships with LBMZ Securities, ZIR, or SCR. The content of this or any other blog, or my Twitter, is at my full discretion.

ADDITIONAL INFORMATION

This blog is for informational purposes only. Articles and Tweets are based on information obtained from sources I believe to be reliable, but I cannot guarantee to be accurate nor do I purport to be complete. Because of individual objectives, articles or Tweets should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk, and investment in biotechnology stocks involves significant risk. Investors should be aware of these risks and consult a certified financial planner (CFP) before making investment decisions. I am not a CFP. By visiting this blog or my Twitter, investors understand and assume full responsibility for this disclaimer. Any opinions expressed on this blog or via my Twitter are subject to change without notice. Reports or Tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities mentioned herein. Additional information is available upon request.

RATING & RECOMMENDATION

I use the following rating system for securities covered on the blog and for reports published for SCR:

 - Buy: I expect the stock to go higher.
 - Hold: I expect the stock to trend side ways.
 - Neutral: I believe the risk / reward is balanced.
 - Sell: I think the stock is going lower.

Often, reports or articles will have target prices. I do my best to fully explain how these targets are derived. Ratings or price targets reported on Twitter are associated with articles found or linked within this blog, or through research reports distributed by my employer, SCR, or articles published on websites such as Seeking-Alpha or Yahoo-Finance. A rough estimate of the distribution for securities covered on this blog is: Buy- 75%, Hold/Neutral- 20%, Sell- 5%.

To learn more about me, visit the About Me tab above.

Jason Napodano, CFA

Blog Archive